Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
Chubb
Healthtrust
Merck
Federal Trade Commission
Argus Health
US Army
QuintilesIMS

Generated: July 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,034,809

« Back to Dashboard

Title:Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Abstract: Enantiomerically pure compounds of general formula 1 ##STR00001## wherein the groups R.sup.1, R.sup.2, R.sup.3, R.sup.4, and X.sup.- may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
Inventor(s): Lustenberger; Philipp (Basel, CH), Konetzki; Ingo (Warthausen, DE), Sieger; Peter (Mittelbiberach, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Filing Date:Dec 15, 2008
Application Number:12/335,076
Claims:1. A method for the treatment of respiratory complaints comprising administering to a patient a therapeutically effective amount of R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylamino]et- hyl}-4H-benzo[1,4]oxazin-3-one hydrochloride.

2. The method according to claim 1, wherein the treatment is once-a-day.

3. The method according to claim 1, wherein said respiratory complaint is COPD (chronic obstructive pulmonary disease).

4. The method according to claim 3, wherein the treatment is once-a-day.

5. The method according to claim 1, wherein said respiratory complaint is asthma.

6. The method according to claim 5, wherein the treatment is once-a-day.

7. The method according to claim 1, wherein said respiratory complaints are selected from the group consisting of bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis.

8. The method according to claim 7, wherein the treatment is once-a-day.

9. A method for the treatment of respiratory complaints comprising administering to a patient a therapeutically effective amount of R-8-{2-[2-(2,4-Difluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-- hydroxy-4H-benzo[1,4]oxazin-3-one hydrochloride.

10. The method according to claim 9, wherein the treatment is once-a-day.

11. The method according to claim 9, wherein said respiratory complaint is COPD (chronic obstructive pulmonary disease).

12. The method according to claim 11, wherein the treatment is once-a-day.

13. The method according to claim 9, wherein said respiratory complaint is asthma.

14. The method according to claim 13, wherein the treatment is once-a-day.

15. The method according to claim 9, wherein said respiratory complaints are selected from the group consisting of bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis.

16. The method according to claim 15, wherein the treatment is once-a-day.

17. A method for the treatment of respiratory complaints comprising administering to a patient a therapeutically effective amount of R-8-{2-[2-(3,5-Difluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-- hydroxy-4H-benzo[1,4]oxazin-3-one hydrochloride.

18. The method according to claim 17, wherein the treatment is once-a-day.

19. The method according to claim 17, wherein said respiratory complaint is COPD (chronic obstructive pulmonary disease).

20. The method according to claim 19, wherein the treatment is once-a-day.

21. The method according to claim 17, wherein said respiratory complaint is asthma.

22. The method according to claim 21, wherein the treatment is once-a-day.

23. The method according to claim 17, wherein said respiratory complaints are selected from the group consisting of bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis.

24. The method according to claim 23, wherein the treatment is once-a-day.

25. A method for the treatment of respiratory complaints comprising administering to a patient a therapeutically effective amount of R-8-{2-[2-(4-Ethoxyphenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-hydr- oxy-4H-benzo[1,4]oxazin-3-one hydrochloride.

26. The method according to claim 25, wherein the treatment is once-a-day.

27. The method according to claim 25, wherein said respiratory complaint is COPD (chronic obstructive pulmonary disease).

28. The method according to claim 27, wherein the treatment is once-a-day.

29. The method according to claim 25, wherein said respiratory complaint is asthma.

30. The method according to claim 29, wherein the treatment is once-a-day.

31. The method according to claim 25, wherein said respiratory complaints are selected from the group consisting of bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis.

32. The method according to claim 31, wherein the treatment is once-a-day.

33. A method for the treatment of respiratory complaints comprising administering to a patient a therapeutically effective amount of R-8-{2-[2-(4-Fluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-hydr- oxy-4H-benzo[1,4]oxazin-3-one hydrochloride.

34. The method according to claim 33, wherein the treatment is once-a-day.

35. The method according to claim 33, wherein said respiratory complaint is COPD (chronic obstructive pulmonary disease).

36. The method according to claim 35, wherein the treatment is once-a-day.

37. The method according to claim 33, wherein said respiratory complaint is asthma.

38. The method according to claim 37, wherein the treatment is once-a-day.

39. The method according to claim 33, wherein said respiratory complaints are selected from the group consisting of bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks and chronic bronchitis.

40. The method according to claim 39, wherein the treatment is once-a-day.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Merck
Covington
Teva
Fish and Richardson
Moodys
Daiichi Sankyo
Chinese Patent Office
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.